Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70080 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Mengyao Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, National Clinical Research Center for Haematologic Disease, Peking Uni…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
We studied 60 chronic myeloid leukaemia (CML) patients with a prior history of accelerated phase (AP) including de novo AP ( n = 19) and transformation to AP ( n = 4), or tyrosine kinase inhibitor (TKI) therapy failure in the chronic phase (CP, n = 37), who discontinued TKI therapy. Median interval from diagnosis with AP or TKI therapy failure to achieving a deep molecular response (DMR) was 19 months (interquartile range [IQR], 9–30 months). Median TKI treatment and DMR duration were 108 months (IQR, 72–137 months) and 59 months (IQR, 39–87 months) respectively. At a median follow‐up of 21 months (IQR, 11–36 months) after TKI discontinuation, 19 (31%) patients lost the major molecular response (MMR). The 3‐year probability of a sustained MMR was 59% (95% confidence interval [CI], [45%, 78%]). In the multivariable analyses, age at discontinuation 0.1% at 12 months on TKI therapy (reference, ≤0.1%; HR = 3.9 [1.4, 11.5], p = 0.011) were significantly associated with a higher probability of MMR loss after TKI discontinuation. CML patients with a history of AP or TKI therapy failure may achieve successful treatment‐free remission after an adequate TKI therapy duration and a sustained DMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Cell and Gene Therapy for Haematologic Malignancies, National Clinical Research Center for Haematologic Disease, Peking University People's Hospital, Peking University Institute of Haematology,…
- Department of Haematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- National Clinical Research Center for Blood Diseases, Institute of Haematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China.
- State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Haematology, Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medic…
- The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
- Department of Haematology, China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Yu Zhu, Weiming Li, Qian Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, M., Zhang, Y., Liu, B., Zhou, L., Zhu, Y., Li, Z., Zang, S., Liu, Z., Li, W., & Jiang, Q. (2025). Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure. British Journal of Haematology. https://doi.org/10.1111/bjh.70080
Vancouver
Yuan M, Zhang Y, Liu B, Zhou L, Zhu Y, Li Z, et al. Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure. British Journal of Haematology. 2025. doi:10.1111/bjh.70080
BibTeX
@article{Yuan2025,
author = {Yuan, Mengyao and Zhang, Yanli and Liu, Bingcheng and Zhou, Li and Zhu, Yu and Li, Zhenling and Zang, Shaolei and Liu, Zhenfang and Li, Weiming and Jiang, Qian},
title = {Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70080}
}
EUVIMED